Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. Show more

Location: Building 7, Tel Aviv, 6158002, Israel | Website: https://www.chemomab.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

13.5M

52 Wk Range

$2.39 - $9.84

Previous Close

$2.60

Open

$2.56

Volume

146,781

Day Range

$2.56 - $2.85

Enterprise Value

3.976M

Cash

9.365M

Avg Qtr Burn

-3.585M

Insider Ownership

16.73%

Institutional Own.

13.17%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nebokitug Details Primary Sclerosing Cholangitis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.